Staging of renal cell carcinoma: Current concepts

BJU International, Supplement

Volumn 95, Issue 2, 2005, Pages 8-13

  Shvarts, Oleg ^a   Lam, John S ^a   Kim, Hyung L ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER; TUMOR MARKER;

ALGORITHM; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAVA VEIN; CONFERENCE PAPER; DISEASE SEVERITY; HISTOLOGY; HUMAN; INFERIOR CAVA VEIN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; NOMOGRAM; PARTIAL NEPHRECTOMY; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TUMOR NECROSIS; TUMOR THROMBUS; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR NEOPLASMS; VENA CAVA, INFERIOR;

EID: 14644427143     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Flocks RH, Kadesky MC. Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol 1958; 79: 196-201
2. Robson C, Churchill B, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-301
3. Guinan P, Sobin L, Algaba F et al. TNM staging of renal cell carcinoma: Workgroup, 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 992-3
4. Minervini R, Minervini A, Fontana N, Traversi C, Cristofani R. Evaluation of the 1997 tumour, nodes and metastases classification of renal cell carcinoma: experience in 172 patients. BJU Int 2000; 86: 199-202
5. Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001; 91: 354-61
6. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A, Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090-5
7. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence, and TNM staging. J Urol 1999; 162: 1930-3
8. Zisman A, Pantuck A, Chao D et al, Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7cm better correlates with clinical outcome. J Urol 2001; 166: 54-8
9. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 2001; 166: 453-6
10. Targonski PV, Frank W, Stuhldreher D et al. Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes, and metastases stage 1 and stage 2 patients. J Urol 1994; 152: 1389-92
11. Kinouchi T, Saiki S, Meguro N et al. Impact of tumor size on the clinical outcomes of patients with Robson Stage I renal cell carcinoma. Cancer 1999; 85: 689-95
12. Man KR, Bui MH, Pantuck AJ et al. TNM T3A renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003; 169: 899-903
13. Zisman A, Wieder J, Pantuck A et al. Renal cell carcinoma with tumor thrombus extension: biology, role of npehrectomy and response to immunotherapy. J Urol 2003; 169: 909-16
14. Skinner DG, Colvin RB, Vermillion CD. Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathological study of 309 cases. Cancer 1971; 28: 1165-77
15. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63
16. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 2376-81
17. Amin MB, Tamboli P, Javidan J et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26: 281-91
18. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001; 32: 590-5
19. Oyasu R. Renal cancer: histologic classification update. Int J Clin Oncol 1998; 3: 125
20. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma, biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17: 523-8
21. Chao D, Zisman A, Pantuck AJ et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002; 161: 71-4
22. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based in tumor stage, size, grade, and necrosis: the SSIGN score. J Urol 2002; 168: 2395-400
23. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 2003; 170: 768-72
24. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000; 163: 426-30
25. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol 2004; 171: 1810-3
26. Citterio G, Bertuzzi A, Tresoldi M et al. Prognostic factors for survival in metastatic renal call carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 1997; 31: 286-91
27. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 7310-3
28. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40
29. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-57
30. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166: 63-7
31. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-52
32. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-66
33. Bonsib SM. Risk and prognosis in renal neoplasms. A pathologist's perspective. Urol Clin North Am 1999; 26: 643-60
34. Di Silverio F, Casale P, Collella D, Andrea L, Seccareccia F, Sciarra A. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer 2000; 88: 835-43
35. Delahunt B, Ribas JL, Nacey JN, Bethwaite PB. Nucleolar organizer regions and prognosis in renal cell carcinoma. J Pathol 1991; 163: 31-7
36. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996; 77: 164-71
37. Yasunaga Y, Shin M, Miki T, Okuyama A, Aozasa K. Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 1998; 68: 11-8
38. Jochum W, Schroder S, al-Tahi R et al. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining and DNA cytophotometry. Cancer 1996; 77: 514-21
39. Onda H, Yasuda M, Serizawa A, Osamura RY, Kawamura N. Clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen, and tumor size. Oncol Rep 1999; 6: 1039-43
40. Rioux-Leclercq N, Turlin B, Bansard J et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal call carcinoma. Urology 2000; 55: 501-5
41. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol 1997; 31: 350-5
42. Visapaa H, Bui M, Huang Y et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal cell carcinoma. Urology 2003; 61: 845-50
43. Morell-Quadreny L, Clar-Blanch F, Fenollosa-Enterna B, Perez-Bacete M, Martinez-Lorente A, Llombart-Bosch A. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res 1998; 18: 677-82
44. Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S. MN/CA9 gene as a potential biomarker in renal cell carcinoma. BJU Int 1999; 83: 743-7
45. Bui M, Seligson D, Han K. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-11